featured
Pertuzumab and Trastuzumab for HER2-Positive, Metastatic Biliary Tract Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pertuzumab and Trastuzumab for HER2-Positive, Metastatic Biliary Tract Cancer (MyPathway): A Multicentre, Open-Label, Phase 2a, Multiple Basket Study
Lancet Oncol 2021 Jul 30;[EPub Ahead of Print], M Javle, MJ Borad, NS Azad, R Kurzrock, GK Abou-Alfa, B George, J Hainsworth, F Meric-Bernstam, C Swanton, CJ Sweeney, CF Friedman, R Bose, DR Spigel, Y Wang, J Levy, K Schulze, V Cuchelkar, A Patel, H BurrisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.